Successful Deals with PwC: Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd.

The terms of the deal include a purchase consideration of MCHF 435 for 100% of the share capital and an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple. The earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.

OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.

Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.

PwC Deals supported Vifor and OM Pharma with Financial and Carve-out related Vendor Assistance.


Deal team

Nico Psarras

Partner, Transaction Services, Zurich, PwC Switzerland

+41 58 792 15 72

Email

Luca Borrelli

Partner, Pharma and Life Sciences, Zurich, PwC Switzerland

+41 58 792 22 78

Email

Rense Balk

Advisory Director, Zurich, PwC Switzerland

+41 58 792 2504

Email

Gregory Mustillo

Advisory Manager, Zurich, PwC Switzerland

+41 58 792 2429

Email

Quoc Fu Ha

Advisory Assistant, Zürich, PwC Switzerland

+41 58 792 4521

Email

 

Successful Deals with PwC

{{filterContent.facetedTitle}}

{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}
{{contentList.loadingText}}

Contact us

Nico Psarras

Nico Psarras

Partner, Transaction Services, PwC Switzerland

Tel: +41 58 792 15 72

Luca Borrelli

Luca Borrelli

Partner, Pharma and Life Sciences, PwC Switzerland

Tel: +41 58 792 22 78